Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Oncology and Therapy|June 26, 2026
Podcast on the Emerging Role of PD-(L)1/VEGF Bispecific Antibodies in the Evolving Advanced Renal Cell Carcinoma Treatment LandscapeBrian I Rini, Benjamin Garmezy
Oncology and Therapy|October 2, 2024
Understanding Treatment Decisions and Management for Patients with Advanced Renal Cell Carcinoma Using Hypothetical Case Studies: A VodcastBenjamin Garmezy, Ulka Vaishampayan
Oncology (Williston Park, N.Y.)|September 26, 2009
Choosing treatment for stage I seminoma: who should get what?Benjamin Garmezy, Lance C Pagliaro
Oncology and Therapy|August 15, 2025
Treatment Optimization and Management of AEs with Enfortumab Vedotin + Pembrolizumab for Untreated Locally Advanced/Metastatic Urothelial Cancer: A PodcastThomas Powles, Maria Lapuente, Benjamin Garmezy
Blood Reviews|May 2, 2020
A provider's guide to primary myelofibrosis: pathophysiology, diagnosis, and managementBenjamin Garmezy, Jordan K Schaefer, Jessica Mercer, et al.
Journal of Bone Oncology|November 8, 2021
All bone metastases are not created equal: Revisiting treatment resistance in renal cell carcinomaAva Brozovich, Benjamin Garmezy, Tianhong Pan, et al.
Journal of Clinical Medicine|October 26, 2024
Clinical Meaningfulness of an Algorithm-Based Service for Analyzing Treatment Response in Patients with Metastatic Cancer Using FDG PET/CTManojkumar Bupathi, Benjamin Garmezy, Michael Lattanzi, et al.
Oncogene|July 10, 2025
Salvage therapy with allogeneic invariant natural killer cells in a heavily pre-treated germ cell tumorBenjamin Garmezy, Joseph E Grossman, Jennifer Buell, et al.
Cancer Research Communications|April 11, 2024
A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid TumorsBenjamin Garmezy, Mitesh J Borad, Rastilav Bahleda, et al.
Cancer Chemotherapy and Pharmacology|January 6, 2026
A phase 1, first-in-human, dose escalation study of JNJ-80038114, a PSMAxCD3 bispecific antibody, in participants with metastatic castration-resistant prostate cancerAndrew Hudson, Anuradha Jayaram, Benjamin Garmezy, et al.
Pageof 2